{"id":"W2105206040","doi":"10.1212/wnl.0000000000000560","title":"Defining the clinical course of multiple sclerosis","year":2014,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3133,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; EMD Serono; Acorda Therapeutics; University of Cambridge; Bayer Canada; National Institutes of Health; Multiple Sclerosis Society; Schweizerische Multiple Sklerose Gesellschaft; Eisai; National Institute for Health and Care Research; National Research Foundation; Wolfson Foundation; Genentech; European Commission; Glenmark Pharmaceuticals; Multiple Sclerosis International Federation; Sanofi; GW Pharmaceuticals; Alexion Pharmaceuticals; Myelin Repair Foundation; Bayer HealthCare; Grifols; F. Hoffmann-La Roche; Ironwood Pharmaceuticals, Incorporated; Eli Lilly and Company; University of Alabama; Wellcome Trust; European Committee for Treatment and Research in Multiple Sclerosis; Sanofi Genzyme; University of Alabama at Birmingham; Medical Research Council; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline; University of Texas Health Science Center at Houston; Celgene; Natural Sciences and Engineering Research Council of Canada; Pfizer; Biogen; Serono Symposia International Foundation; Novartis Pharmaceuticals Corporation; National Multiple Sclerosis Society; National Heart, Lung, and Blood Institute; Sun Pharma; Cleveland Clinic; Canadian Institutes of Health Research; Prothena; Amylin Pharmaceuticals","keywords":"Multiple sclerosis; Clinical trial; Clinical phenotype; Disease; Medicine; Clinical disease; Phenotype; Medical physics; Pathology; Intensive care medicine; Bioinformatics; Biology; Psychiatry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}